KY 0301
Alternative Names: KY-0301; RB-601Latest Information Update: 09 Sep 2025
At a glance
- Originator Novatim Immune Therapeutics (Zhejiang)
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Epidermal growth factor modulators; Proto-oncogene protein c-met modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer; Solid tumours
Most Recent Events
- 03 Sep 2025 KY 0301 licensed to Radiance Biopharma worldwide excluding Mainland China, Hongkong, Taiwan and Macau
- 03 Sep 2025 Phase-I clinical trials in Non-small cell lung cancer in China (Parenteral), prior to September 2025 (Radiance Biopharma pipeline, September 2025)
- 03 Sep 2025 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (Parenteral), prior to September 2025